| Catalog No. | DW431028 |
|---|
| Sample type | Plasma, Serum |
|---|
| Sensitivity | 0.156 μg/ml |
|---|
| Range | 0.31-5 μg/mL |
|---|
| Accession |
P40259 |
| Applications |
ELISA |
| Detection method |
Colorimetric |
| Assay type |
Quantitative |
| Recovery |
80-120% |
| Shipping |
2-8 ℃ |
| Stability and Storage |
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| Specifications |
Polatuzumab
|
| Alternate Names | ACD79B-VCMMAE, DCDS4501A, FCU2711, RO5541077-000, polatuzumab vedotin-piiq, 1313206-42-6 |
|---|
| Background | Polatuzumab vedotin is an antibody-drug conjugate formed by a CD79b antibody conjugated to the highly cytotoxic agent monomethyl auristatin E by means of a cleavable linker. Following significant clinical efficacy in R/R DLBCL, polatuzumab vedotin was granted accelerated Food and Drug Administration (FDA) approval in combination with bendamustine plus rituximab for patients who have failed at least two prior therapies. Other clinical studies involving polatuzumab vedotin in combination with other therapy regimens are also under evaluation for previously untreated DLBCL patients. |
|---|
| Note |
For Research Use Only. |
